Bacterial Enzyme an Antismoking Aid?

A compound that degrades nicotine before it reaches the brain could serve as a successful smoking cessation therapy, according to an in vitro study.

Written byJef Akst
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

FLICKR, MATT TROSTLEAvailable treatments for quitting smoking fail in the vast majority of those who try them, but a new study points to a bacterial enzyme that may prove more successful. Pseudomonas putida, a soil bacterium first isolated from a tobacco field, gets all its carbon and nitrogen by consuming nicotine. And a P. putida enzyme called NicA2 is responsible for breaking down nicotine, according to a study published last week (August 6) in the Journal of the American Chemical Society.

“The bacterium is like a little Pac-Man. It goes along and eats nicotine,” coauthor Kim Janda of the Scripps Research Institute in La Jolla, California, said in a press release. “Our research is in the early phase of drug development process, but the study tells us the enzyme has the right properties to eventually become a successful therapeutic.” If NicA2 can degrade nicotine before it reaches the brain’s reward centers, it could help a smoker kick the habit by blocking a pleasurable feeling they get from cigarettes.

Sure enough, when the researchers spiked mouse serum with a dose of nicotine equivalent to one cigarette, then added NicA2 to the mix, the enzyme cut nicotine’s half-life from more than two hours to less than 15 minutes. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies